BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 20015102)

  • 1. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
    Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
    Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
    Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
    Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.
    Min MX; Weinberg DI; McCabe RP
    J Clin Pharm Ther; 2014 Apr; 39(2):107-11. PubMed ID: 24438369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
    Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA
    Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):563-7. PubMed ID: 15317038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.
    Vasudevan A; Beswick L; Friedman AB; Moltzen A; Haridy J; Raghunath A; Sparrow M; van Langenberg D
    Dig Liver Dis; 2018 Jul; 50(7):682-688. PubMed ID: 29525182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
    Korelitz BI; Mirsky FJ; Fleisher MR; Warman JI; Wisch N; Gleim GW
    Am J Gastroenterol; 1999 Nov; 94(11):3248-53. PubMed ID: 10566724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
    Gazouli M; Pachoula I; Panayotou I; Mantzaris G; Syriopoulou VP; Goutas N; Vlachodimitropoulos D; Anagnou NP; Roma-Giannikou E
    J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.
    Daperno M; Sostegni R; Canaparo R; Serpe L; Lavagna A; Crocellà L; Castagno F; Vernetto A; Rigazio C; Ercole E; D'Antico S; Pera A; Zara G; Rocca R
    Aliment Pharmacol Ther; 2009 Oct; 30(8):843-53. PubMed ID: 19650826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.
    Kiszka-Kanowitz M; Theede K; Mertz-Nielsen A
    Scand J Gastroenterol; 2016 Dec; 51(12):1470-1475. PubMed ID: 27686002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.
    Hindorf U; Lindqvist M; Hildebrand H; Fagerberg U; Almer S
    Aliment Pharmacol Ther; 2006 Jul; 24(2):331-42. PubMed ID: 16842460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
    Cao Q; Zhu Q; Shang Y; Gao M; Si J
    Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio.
    Gardiner SJ; Gearry RB; Burt MJ; Chalmers-Watson T; Chapman BA; Ross AG; Stedman CA; Huelsen A; Barclay ML
    J Gastroenterol Hepatol; 2011 Jan; 26(1):49-54. PubMed ID: 21175793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M; Theede K; Nielsen AM
    Ugeskr Laeger; 2015 Jun; 177(26):1253-5. PubMed ID: 26550625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.
    Seinen ML; van Asseldonk DP; de Boer NK; Losekoot N; Smid K; Mulder CJ; Bouma G; Peters GJ; van Bodegraven AA
    J Crohns Colitis; 2013 Nov; 7(10):812-9. PubMed ID: 23317929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
    Banerjee S; Bishop WP
    J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):324-30. PubMed ID: 16954954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
    Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
    Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.